National Guideline Clearinghouse | Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis.

National Guideline Clearinghouse | Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis.

National Institute for Health and Care Excellence (NICE)

• Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis.

Guideline Title Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis. Bibliographic Source(s) National Institute for Health and Care Excellence (NICE). Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis. London (UK): National Institute for Health and Care Excellence (NICE); 2015 Dec 16. 57 p. (Technology appraisal guidance; no. 373).  Guideline Status This is the current release of the guideline. This guideline meets NGC's 2013 (revised) inclusion criteria.